Skip to content

Randomized and controlled clinical trials based on the "muscle controlled by the spleen" to explore the safety and effectiveness of Shen-ling-bai-zhu-san in the treatment of COPD with myolemia.

Randomized and controlled clinical trials based on the "muscle controlled by the spleen" to explore the safety and effectiveness of Shen-ling-bai-zhu-san in the treatment of COPD with myolemia.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000699
Enrollment
Unknown
Registered
2025-04-11
Start date
2024-07-30
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD with sarcopenia

Interventions

Control group:Blank control, that is, no traditional Chinese medicine treatment is given.
Experimental group :Senling Baizhu San

Sponsors

Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the above diagnostic criteria can be regarded as test cases. (2) The age is between 40 and 80 years old. (3) Patients with COPD in a stable period and no history of acute aggravation in the past 4 weeks. (4) Those who can complete the lung function measurement. (5) Those who have signed the informed consent form voluntarily participate in this experiment.

Exclusion criteria

Exclusion criteria: (1) The subject is pregnant breastfeeding or planning to become pregnant; 2) Active lung infection or past lung infection that has been treated with antibiotics and/or steroids before =4 weeks; (3) Combined with other known serious lung diseases including asthma active tuberculosis clinically significant bronchiectasis bronchial asthma lung cancer pneumothorax etc.; (4) Combined with severe primary diseases such as heart liver kidney and hematopoietic systems mental illness or any other researcher believes may threaten the patient's safety interfere with the evaluation or hinder the completion of the study; (5) Patients who are allergic to any research drugs or similar chemically classified drugs; (6) Patients who cannot successfully use a dry powder inhaler or cannot perform lung function measurement; (7) Those who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Skeletal Muscle Mass Index,SMI);hand grip strength,HGS;pulmonary function;Walking speed;

Secondary

MeasureTime frame
St. Georges Respiratory Questionnaire SGRQ;modified Medical Research Council Dyspnea Scale,mMRC;6-minute walk test (6MWT);Clinical COPD Questionnaire,CCQ;COPD assessment test,CAT;BODE;

Countries

China

Contacts

Public ContactZengzhu

Hospital of Chengdu University of Traditional Chinese Medicine

zengzhu@cdutcm.edu.cn15184443280

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026